查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1541700

2024-2032 年替米沙坦市场报告（按适应症（高血压、降低心血管风险）、配销通路（医院药房、药局和零售药房、网路商店）和地区）

Telmisartan Market Report by Indication (Hypertension, Cardiovascular Risk Reduction), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Stores), and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 150 Pages | 商品交期: 2-3个工作天内

价格

IMARC Group年，全球替米沙坦市场规模达37亿美元。

替米沙坦是一种非胜肽类血管张力素受体阻断剂（ARB），用作治疗高血压和心血管疾病的处方药。它通常以片剂和口服油悬浮液形式提供，并与其他药物一起服用以增强其功效。它具有抗高血压特性并抑制体内醛固酮的产生，从而减少钠和水的吸收，从而降低血压。替米沙坦还可以放鬆血管并促进肾功能。然而，它可能会引起各种副作用，例如头晕、头晕、咳嗽和鼻窦疼痛。

替米沙坦市场趋势：

全球製药业的显着成长是创造积极市场前景的关键因素之一。此外，高血压、糖尿病和各种肾臟相关疾病的盛行率不断上升，也推动了市场的成长。替米沙坦已被证明可以有效修改胰岛素敏感性基因以及调节葡萄糖和脂质代谢，有助于治疗慢性糖尿病肾病变和久坐生活方式引起的其他疾病。药厂也推出替米沙坦药物的仿製药，为高血压和心血管疾病提供经济有效的治疗。此外，药品製造商正在大力投资用于治疗糖尿病肾病变的先进替米沙坦药物的研发（R＆D），这也促进了市场的成长。其他因素，包括老年人口的增加以及医疗基础设施的显着改善，预计将进一步推动市场。

本报告回答的关键问题：

  • 迄今为止，全球替米沙坦市场表现如何，未来几年将如何表现？
  • COVID-19 对全球替米沙坦市场有何影响？
  • 主要区域市场有哪些？
  • 根据指示，市场的细分是什么？
  • 基于配销通路的市场区隔是什么？
  • 产业价值链的各个阶段是什么？
  • 该行业的关键驱动因素和挑战是什么？
  • 全球替米沙坦市场的结构如何？
  • 产业竞争程度如何？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 数据来源
    • 主要来源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球替米沙坦市场

  • 市场概况
  • 市场表现
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：依迹象

  • 高血压
    • 市场趋势
    • 市场预测
  • 降低心血管风险
    • 市场趋势
    • 市场预测

第 7 章：市场区隔：按配销通路

  • 医院药房
    • 市场趋势
    • 市场预测
  • 药局和零售药局
    • 市场趋势
    • 市场预测
  • 网上商店
    • 市场趋势
    • 市场预测

第 8 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场趋势
    • 市场细分：按国家/地区
    • 市场预测

第 9 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 10 章：价值链分析

第 11 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 12 章：价格分析

第13章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Abbott Laboratories
    • Aurobindo Pharma USA
    • Boehringer Ingelheim International GmbH
    • Cipla Limited
    • Hikma Pharmaceuticals plc
    • Jubilant Cadista Pharmaceutical
    • Sanofi SA
    • Solco Healthcare (Prinston Pharmaceutical Inc.)
    • Torrent Pharmaceuticals Ltd
Product Code: SR112024A4074

The global telmisartan market size reached US$ 3.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 4.8 Billion by 2032, exhibiting a growth rate (CAGR) of 2.7% during 2024-2032.

Telmisartan is a non-peptide angiotensin receptor blocker (ARB), which is used as a prescription drug for the treatment of hypertension and cardiovascular disorders. It is commonly available in tablets and oral oil suspension variants and is administered with other medications to enhance its efficacy. It exhibits antihypertensive properties and inhibits aldosterone production in the body, thereby leading to a decrease in sodium and water absorption and subsequent reduction in the blood pressure. Telmisartan also relaxes the blood vessels and promotes kidney function. However, it may cause various side effects, such as dizziness, lightheadedness, cough and sinus pain.

Telmisartan Market Trends:

Significant growth in the pharmaceutical industry across the globe is one of the key factors creating a positive outlook for the market. Moreover, the increasing prevalence of high blood pressure, diabetes and various kidney-related disorders is providing a thrust to the market growth. Telmisartan has been proven effective in modifying genes for insulin sensitization and regulating glucose and lipid metabolism, which aids in managing chronic diabetic kidney disease and other disorders caused by sedentary lifestyles. Pharmaceutical manufacturers are also launching generic versions of telmisartan medications to provide cost-effective treatment to hypertension and cardiovascular ailments. Additionally, drug manufacturers are investing significantly in the research and development (R&D) of advanced telmisartan medications for the treatment of diabetic nephropathy, which is also contributing to the growth of the market. Other factors, including the rising geriatric population, along with significant improvements in the healthcare infrastructure, are anticipated to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global telmisartan market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on indication and distribution channel.

Breakup by Indication:

Hypertension

Cardiovascular Risk Reduction

Breakup by Distribution Channel:

Hospital Pharmacies

Drug Stores and Retail Pharmacies

Online Stores

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Aurobindo Pharma USA, Boehringer Ingelheim International GmbH, Cipla Limited, Hikma Pharmaceuticals plc, Jubilant Cadista Pharmaceutical, Sanofi S.A., Solco Healthcare (Prinston Pharmaceutical Inc.) and Torrent Pharmaceuticals Ltd.

Key Questions Answered in This Report:

  • How has the global telmisartan market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global telmisartan market?
  • What are the key regional markets?
  • What is the breakup of the market based on the indication?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global telmisartan market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Telmisartan Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Indication

  • 6.1 Hypertension
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Cardiovascular Risk Reduction
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Distribution Channel

  • 7.1 Hospital Pharmacies
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Drug Stores and Retail Pharmacies
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Online Stores
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia-Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Abbott Laboratories
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 Aurobindo Pharma USA
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
    • 13.3.3 Boehringer Ingelheim International GmbH
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
    • 13.3.4 Cipla Limited
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 Hikma Pharmaceuticals plc
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
      • 13.3.5.4 SWOT Analysis
    • 13.3.6 Jubilant Cadista Pharmaceutical
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
    • 13.3.7 Sanofi S.A.
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
      • 13.3.7.4 SWOT Analysis
    • 13.3.8 Solco Healthcare (Prinston Pharmaceutical Inc.)
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
    • 13.3.9 Torrent Pharmaceuticals Ltd
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
      • 13.3.9.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Telmisartan Market: Major Drivers and Challenges
  • Figure 2: Global: Telmisartan Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Telmisartan Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Telmisartan Market: Breakup by Indication (in %), 2023
  • Figure 5: Global: Telmisartan Market: Breakup by Distribution Channel (in %), 2023
  • Figure 6: Global: Telmisartan Market: Breakup by Region (in %), 2023
  • Figure 7: Global: Telmisartan (Hypertension) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 8: Global: Telmisartan (Hypertension) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 9: Global: Telmisartan (Cardiovascular Risk Reduction) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Telmisartan (Cardiovascular Risk Reduction) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Telmisartan (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Telmisartan (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Telmisartan (Drug Stores and Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Telmisartan (Drug Stores and Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Telmisartan (Online Stores) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Telmisartan (Online Stores) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: North America: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: North America: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: United States: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: United States: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Canada: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Canada: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Asia-Pacific: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Asia-Pacific: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: China: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: China: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Japan: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Japan: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: India: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: India: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: South Korea: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: South Korea: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Australia: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Australia: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Indonesia: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Indonesia: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Others: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Others: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Europe: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Europe: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Germany: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Germany: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: France: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: France: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: United Kingdom: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: United Kingdom: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Italy: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Italy: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Spain: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Spain: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: Russia: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: Russia: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Others: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Others: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Latin America: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Latin America: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Brazil: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Brazil: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Mexico: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Mexico: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Others: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Others: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Middle East and Africa: Telmisartan Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Middle East and Africa: Telmisartan Market: Breakup by Country (in %), 2023
  • Figure 65: Middle East and Africa: Telmisartan Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Global: Telmisartan Industry: SWOT Analysis
  • Figure 67: Global: Telmisartan Industry: Value Chain Analysis
  • Figure 68: Global: Telmisartan Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Telmisartan Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Telmisartan Market Forecast: Breakup by Indication (in Million US$), 2024-2032
  • Table 3: Global: Telmisartan Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 4: Global: Telmisartan Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 5: Global: Telmisartan Market: Competitive Structure
  • Table 6: Global: Telmisartan Market: Key Players